Dhe great success with the corona vaccines has brought BioNTech a huge leap in profit. As the biotechnology company from Mainz announced on Monday, the profit in the second quarter was 2.8 billion euros. The enormous development behind this number is shown by a look at the same period in the previous year, when BioNTech still made a loss of 88.3 million euros.
Overall, the net profit in the first half of the current year was 3.9 billion euros, in the same period of 2020, however, there was a minus of a good 141 million euros. The company, which has been listed on the stock exchange since 2019, posted sales of 5.3 billion euros for the quarter that ended in June, compared with 41.7 million in the second quarter of 2020.
In the meantime, BioNTech, together with its American partner Pfizer, has passed the one billion Covid 19 vaccine dose mark six months after the start of delivery of its mRNA vaccine, as BioNTech announced. The liquid has been shipped to over 100 countries or regions.
Rapid price increase
BioNTech estimates that it will have delivered around 2.2 billion vaccine doses by the end of the year, and sales will then be around 15.9 billion euros. In addition, additional sales in connection with further supply contracts can be expected in 2021; The total production capacity for the current year is three billion cans, and four billion are set for 2022. BioNTech and Pfizer had received the world’s first approval for a Covid-19 vaccine at the end of 2020.
Biontech share
—
— (–)
To the detailed view
After the figures were published, the positive development of the share price continued on the stock exchange. The BioNTech paper increased by around five percent over the course of the day and currently costs more than $ 400 each on the American Nasdaq. When it went public in 2019, it was only $ 15. This corresponds to a price increase of around 2500 percent.
Due to the rapid rise in the share price, the shares of company founder Ugur Sahin, who holds a good 17 percent in BioNTech, are now worth a good 13 billion euros. According to a list by the Bloomberg news agency, he is also one of the ten richest Germans.
BioNTech is advancing the fight against diseases other than Corona. Sahin said the pipeline had been developed in the oncology field and hoped to bring a number of product candidates to market in the next few years. Research and development costs in the second quarter were over EUR 200 million compared to EUR 95 million in the same period of the previous year.
.